Surface Oncology ROE 2017-2018 | SURF
Current and historical return on equity (ROE) values for Surface Oncology (SURF) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Surface Oncology ROE for the three months ending December 31, 2018 was -8.52%.
|Surface Oncology ROE - Return on Equity Historical Data
||TTM Net Income
||Return on Equity
||Medical Products Manufacturing
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.